Lifecore Biomedical
LFCR
88 hedge funds and large institutions have $190M invested in Lifecore Biomedical in 2025 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 4 closing their positions.
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
58% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 19
13% more funds holding
Funds holding: 78 → 88 (+10)
1.17% less ownership
Funds ownership: 67.43% → 66.26% (-1.2%)
11% less call options, than puts
Call options by funds: $24K | Put options by funds: $27K
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
35% less capital inflows, than outflows
Capital inflows: $4.85M | Capital outflows: $7.45M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$922K |
| 2 |
LPL Financial
San Diego,
California
|
+$907K |
| 3 |
Millennium Management
New York
|
+$627K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$402K |
| 5 |
Boston Partners
Boston,
Massachusetts
|
+$212K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$4.13M |
| 2 |
Boothbay Fund Management
New York
|
-$647K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$406K |
| 4 |
DA
DCF Advisers
Greenwich,
Connecticut
|
-$354K |
| 5 |
Rangeley Capital
New Canaan,
Connecticut
|
-$325K |
LFCR Hedge Fund Activity: Q1 2025 in Review
88 of the 7,487 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2025, worth a combined $190M — down 6.1% from $203M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LFCR positions and 4 closed out — a net gain of 11 holders — while 30 added to existing stakes and 19 trimmed.
The largest buyer was BlackRock, adding an estimated $922K. The largest seller was Invesco, exiting entirely with an estimated $4.13M sold.
- 88 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2025, up from 78 in Q4 2024.
- Funds reported $190M of Lifecore Biomedical stock for Q1 2025, down 6.1% quarter-over-quarter.
- 15 funds opened new Lifecore Biomedical positions in Q1 2025 and 4 closed out, a net change of +11 holders.
- The largest Lifecore Biomedical buyer in Q1 2025 was BlackRock, an estimated $922K added.
- The largest Lifecore Biomedical seller in Q1 2025 was Invesco, an estimated $4.13M sold.
Based on aggregated 13F filings for Q1 2025.